Trials / Active Not Recruiting
Active Not RecruitingNCT06410924
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Treatment With DD01 for 48 Weeks in Overweight/Obese Subjects With MASLD/MASH
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Neuraly, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DD01 | Dual GLP-1 and glucagon receptor agonist |
| DRUG | Placebo | Placebo matching DD01 |
Timeline
- Start date
- 2024-06-13
- Primary completion
- 2025-05-20
- Completion
- 2026-04-22
- First posted
- 2024-05-13
- Last updated
- 2026-04-08
Locations
12 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06410924. Inclusion in this directory is not an endorsement.